Quest Diagnostics Incorporated (DGX)
NYSE: DGX · Real-Time Price · USD
178.48
-0.56 (-0.31%)
Aug 14, 2025, 2:25 PM - Market open
Quest Diagnostics Employees
As of December 31, 2024, Quest Diagnostics had 56,000 total employees, including 45,000 full-time and 11,000 part-time employees. The number of employees increased by 8,000 or 16.67% compared to the previous year.
Employees
56,000
Change (1Y)
8,000
Growth (1Y)
16.67%
Revenue / Employee
$187,893
Profits / Employee
$16,875
Market Cap
19.96B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56,000 | 8,000 | 16.67% |
Dec 31, 2023 | 48,000 | -1,000 | -2.04% |
Dec 31, 2022 | 49,000 | 0 | - |
Dec 31, 2021 | 49,000 | 0 | - |
Dec 31, 2020 | 49,000 | 2,000 | 4.26% |
Dec 31, 2019 | 47,000 | 1,000 | 2.17% |
Dec 31, 2018 | 46,000 | 1,000 | 2.22% |
Dec 31, 2017 | 45,000 | 2,000 | 4.65% |
Dec 31, 2016 | 43,000 | -1,000 | -2.27% |
Dec 31, 2015 | 44,000 | -1,000 | -2.22% |
Dec 31, 2014 | 45,000 | 4,000 | 9.76% |
Dec 31, 2013 | 41,000 | 0 | - |
Dec 31, 2012 | 41,000 | -1,000 | -2.38% |
Dec 31, 2011 | 42,000 | 0 | - |
Dec 31, 2010 | 42,000 | -1,000 | -2.33% |
Dec 31, 2009 | 43,000 | 200 | 0.47% |
Dec 31, 2008 | 42,800 | -700 | -1.61% |
Dec 31, 2007 | 43,500 | 2,500 | 6.10% |
Dec 31, 2006 | 41,000 | -500 | -1.20% |
Dec 31, 2005 | 41,500 | 2,900 | 7.51% |
Dec 31, 2004 | 38,600 | 1,400 | 3.76% |
Dec 31, 2003 | 37,200 | 3,800 | 11.38% |
Dec 31, 2002 | 33,400 | 4,400 | 15.17% |
Dec 31, 2001 | 29,000 | 2,000 | 7.41% |
Dec 31, 2000 | 27,000 | 0 | - |
Dec 31, 1999 | 27,000 | 12,000 | 80.00% |
Dec 31, 1998 | 15,000 | -1,300 | -7.98% |
Dec 31, 1997 | 16,300 | -1,500 | -8.43% |
Dec 31, 1996 | 17,800 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
DGX News
- 19 hours ago - Quest Diagnostics Declares Quarterly Cash Dividend - PRNewsWire
- 7 days ago - Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types - PRNewsWire
- 9 days ago - Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care - PRNewsWire
- 16 days ago - Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing - PRNewsWire
- 23 days ago - Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks - Benzinga
- 23 days ago - Quest Diagnostics Incorporated (DGX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Quest Diagnostics raises annual forecasts on strong diagnostic testing demand - Reuters
- 23 days ago - Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 - PRNewsWire